Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study
Immunotherapy · 2023
DOI: 10.2217/imt-2022-0145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy, 2023. Verfasst von Yinghong Zhai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, School of Medicine, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, 200011, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Three-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System, Military Key Discipline Construction Project, The Shanghai Municipal Commission of Health and Family Planning Fund for Excellent Young Scholars.
Abstract (Originalsprache)
Aim
Comprehensively characterize the cardiotoxicity of CD19-directed chimeric antigen receptor T-cell (CAR-T) products. Materials & methods: Data between 2017 and 2021 in the US FDA's Adverse Event Reporting System database were utilized. Disproportionality was measured using reporting odds ratio and information component. Hierarchical clustering analysis was performed to explore the relationships among cardiac events.
Results
Tisagenlecleucel exhibited the highest percentage of death (53.24%) and life-threatening (13.39%) outcomes. Axicabtagene ciloleucel and tisagenlecleucel were equal in the number of positive signals (n = 15), while the former had excessive reporting of several cardiac events versus the latter, such as atrial fibrillation, cardiomyopathy, cardiorenal syndrome and sinus bradycardia.
Conclusion
Several cardiac risks should be considered for CAR-T treatment and these events might vary in frequency and severity following different CAR-T agents. Chimeric antigen receptor T-cell (CAR-T) therapy is effective in a wide spectrum of malignancies. However, the complete cardiotoxicity profile associated with this new treatment has not been characterized. This study systematically analyzed the reported cardiac events of four approved CAR-T agents using the US FDA's Adverse Event Reporting System database. It indicated that the type of cardiac events was broad and overlapped a lot with cytokine release syndrome. Pre-therapy assessment, intensive monitoring and appropriate intervention were critical to reduce the level of cardiac damage or the rate of mortality in patients receiving CAR-T.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Center, School of Medicine, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, 200011, China.
- Department of Medical Service, Naval Hospital of Eastern theater, Zhejiang Zhoushan, 316000, China.
- Department of Health Statistics, Second Military Medical University, Shanghai, 200433, China.
- Tongji University School of Medicine, 1239 Siping Road, Yangpu District, Shanghai, 200092, China.
ORCID-Profile: Yinghong Zhai, Jia He
Förderung
- Three-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System
- Military Key Discipline Construction Project
- The Shanghai Municipal Commission of Health and Family Planning Fund for Excellent Young Scholars
- The Excellent Young Scholars of public health in Shanghai
- The National Nature Science Foundation of China
- The Leading Talents of Public Health in Shanghai
Zitieren
APA
Zhai, Y., Hu, F., Zhu, B., Xu, J., Guo, X., Shi, W., Zhou, X., Zheng, Y., Xu, X., Ye, X., He, J., & Xu, F. (2023). Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study. Immunotherapy. https://doi.org/10.2217/imt-2022-0145
Vancouver
Zhai Y, Hu F, Zhu B, Xu J, Guo X, Shi W, et al. Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study. Immunotherapy. 2023. doi:10.2217/imt-2022-0145
BibTeX
@article{Zhai2023,
author = {Zhai, Yinghong and Hu, Fangyuan and Zhu, Borui and Xu, Jinfang and Guo, Xiaojing and Shi, Wentao and Zhou, Xiang and Zheng, Yi and Xu, Xiao and Ye, Xiaofei and He, Jia and Xu, Feng},
title = {Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study},
journal = {Immunotherapy},
year = {2023},
doi = {10.2217/imt-2022-0145}
}
EUVIMED